Sign In
Buy AMGN
$345.60
+7.38 (+2.18%)
At Close: Jun 04, 2026
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
01:59pm, Wednesday, 13'th Nov 2024
On Tuesday, a Cantor analyst wrote that additional data from Amgen's experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug.
Trade Tracker: Joe Terranova sells Amgen and buys XBI
01:23pm, Wednesday, 13'th Nov 2024
Joe Terranova, senior managing director for Virtus Investment Partners, joins CNBC's 'Halftime Report' to discuss his latest portfolio moves.
What's Happening With Amgen Stock?
10:31am, Wednesday, 13'th Nov 2024
Amgen stock (NASDAQ: AMGN) saw a 7% fall on Tuesday, November 12, after an update on the progress with its weight-loss drug — MariTide. An early-stage trial for the drug showed loss of bone density,
Amgen sees no bone safety concerns around experimental obesity drug
05:25am, Wednesday, 13'th Nov 2024
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a day after data from an early-stage study dragged its stock 7% lower.
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
05:00am, Wednesday, 13'th Nov 2024
THOUSAND OAKS, Calif. , Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data.
Amgen sinks as Cantor flags issues with obesity drug
06:01pm, Tuesday, 12'th Nov 2024
Olivia Brayer, Cantor Fitzgerald, joins 'Fast Money' to discuss Amgen shares sliding on bone density data.
Amgen stock falls as analysts mull over weight loss drug's bone density data
04:53pm, Tuesday, 12'th Nov 2024
Shares of Amgen fell as analysts chewed over bone density loss data from an early-stage trial on its experimental weight loss injection, MariTide. While some analysts called the additional data a pote
AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE
04:00pm, Friday, 08'th Nov 2024
THOUSAND OAKS, Calif. , Nov. 8, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2024 UBS Global Healthcare Conference at 10:15 a.m.
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
02:00am, Friday, 08'th Nov 2024
Statistically Significant Reduction in Nasal Polyp Size, Nasal Congestion Compared to Placebo THOUSAND OAKS, Calif. , Nov. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced p
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
10:05am, Tuesday, 05'th Nov 2024
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Buy 3 November Dogs Of The Dow And Watch 7 More
04:19am, Saturday, 02'nd Nov 2024
"The Dow® [adds a stock] if the company has an excellent reputation,
Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in Focus
08:46am, Thursday, 31'st Oct 2024
AMGN beats third-quarter estimates for earnings and matches the same for sales. It slightly raises 2024 sales guidance but narrows the EPS range.
Amgen Inc. (AMGN) Q3 2024 Earnings Call Transcript
10:40pm, Wednesday, 30'th Oct 2024
Amgen Inc. (NASDAQ:AMGN ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President Murdo Gordon - EVP, Global
Compared to Estimates, Amgen (AMGN) Q3 Earnings: A Look at Key Metrics
06:31pm, Wednesday, 30'th Oct 2024
The headline numbers for Amgen (AMGN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Amgen (AMGN) Beats Q3 Earnings Estimates
06:16pm, Wednesday, 30'th Oct 2024
Amgen (AMGN) came out with quarterly earnings of $5.58 per share, beating the Zacks Consensus Estimate of $5.11 per share. This compares to earnings of $4.96 per share a year ago.
